[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100088726":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":24,"locations":31,"responsibleParty":24,"collaborators":24,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":24,"acronym":24,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":24,"enrollmentInfo":52,"targetDuration":24,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":63,"whyStopped":24,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":24,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Walter Reed Army Medical Center","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Moxifloxacin","EXPERIMENTAL","Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery",[13],"Drug: Moxifloxacin",{"label":15,"type":10,"description":16,"interventionNames":17},"Gatifloxacin","Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery",[18],"Drug: Gatifloxacin",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery",[9],null,{"type":21,"name":15,"description":22,"armGroupLabels":26,"otherNames":24},[15],[28],{"name":29,"affiliation":5,"role":30},"KRAIG S. BOWER, MD","PRINCIPAL_INVESTIGATOR",[32],{"facility":5,"status":24,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":24},"Washington D.C.","District of Columbia","20307","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-77.03637,38.89511,{"lat":42,"lon":41},"100088726","comparison-of-the-effect-of-4th-generation-fluoroquinolones-gatifloxacin-and-moxifloxacin-on-epithelial-healing-following-photorefractive-keratectomy-prk-a-substudy-of-initial-evaluation-of-excimer-laser-keratorefractive-surgery-in-us-army-personnel-wu--2335-99-100088726",true,"NCT00414011","Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)","Inclusion Criteria:\n\n* Manifest refraction spherical equivalent (MSE) of up to -6.00 diopters (D) at the spectacle plane with refractive cylinder up to 3.00D.\n\nExclusion Criteria:\n\n* Concurrent topical or systemic medications that may impair healing including corticosteroids, antimetabolites, isotretinoin, amiodarone hydrochloride and\u002F or sumatripin.\n* Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.\n* Anterior basement membrane dystrophy.\n* History of recurrent epithelial erosion.\n* Significant dry eye (symptomatic sith Schirmer \\\u003C5mm at 5 minutes)\n* Other corneal epithelial disorder or healing abnormality","ALL","21 Years",{"count":53,"type":54},40,"ACTUAL","INTERVENTIONAL",[57],"NA","The purpose of this study is a prospective,double-blinded, randomized trial to compare the rate of healing following PRK after the use of two commercially available 4th generation fluoroquinolones, moxifloxacin and gatifloxacin.",[60],"Epithelium, Corneal",[62],"Removal of corneal epithelium followed by excimer laser treatment during prk","COMPLETED","2013-06-26",{"date":66,"type":67},"2013-07-17","ESTIMATED",{"date":69,"type":54},"2005-02",{"name":5,"class":6},1]